Yeon Joo (Claire) Hsu, Esq.

P.O. Box 13168, Denver, Colorado 80202
347.255.5964 · claire.hsu1211@gmail.com

September 30, 2016

OTC Markets Group
3rd Floor
304 Hudson Street
New York, New York 10013

RE: Attorney Letter with Respect to Adequate Current Information for Blue Diamond Ventures, Inc.

Dear Sir or Madam:

Please be advised that OTC is entitled to rely on this letter in determining whether Blue Diamond Ventures, Inc. ("Company") has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933.

The undersigned has been retained by the Company for the purpose of rendering this letter and related matters, including reviewing the current information supplied by the Company.

I am a U.S. resident and authorized to practice law in the States of Massachusetts, New York and Colorado. I am permitted to practice before the Securities and Exchange Commission ("SEC") and has not been prohibited from practice thereunder.

Regarding this letter, I have reviewed the Company's Annual Report ("Annual Report") for the period ending June 30, 2016. I have examined such corporate records and other documents and such questions of law as I have considered necessary or appropriate for purposes of rendering this letter. I have assumed:

(i) the authenticity of all documents submitted to me as originals;
(ii) the conformity to the originals of all documents submitted to me as copies;
(iii) the genuineness of all signatures on behalf of parties other than Company and that all necessary documents have been properly executed;
(iv) the due authority, capacity and power of the parties executing the documents on behalf of parties other than Company to enter into and perform all of their respective obligations thereunder;
(v) the due authorization, execution and delivery of the documents by the parties thereto other than Company;
(vi) that the documents constitute the legally valid and binding obligations of the parties thereto other than Company enforceable against such parties in accordance with their terms;

I have relied on information obtained from officers of the Company and other sources. I have no reason to believe that records, certificates, or documents of the Company that I have reviewed are not accurate, authentic or reliable.

The Company has 5,799,499,999 authorized common shares of which 4,760,585,689 are outstanding as of September 30, 2016.

I am of the opinion that the information contained in the Company's Annual Report for the period ending June 30, 2016 (i) constitute "adequate current public information" concerning the Company's securities and the Company and "is available" within the meaning of Rule 144(c)(2) under the Securities Act, (ii) include all of the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"), (iii) complies as to form with the OTC Markets Group Inc.'s OTC Pink Disclosure Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otcmarkets.com and (iv) has been posted through the OTC Disclosure and News Service.

The unaudited financial statements are prepared and reviewed by Benjamin M. Larson, accountant at Polyhedron, LLC, located at 6734 Hollow Dale Drive, Cottonwood Heights, UT 84121.

The Company's transfer agent is Island Stock Transfer ("IST") located at 15500 Roosevelt Boulevard Suite 301, Clearwater, Florida 33760. To the best of my knowledge, and as represented by IST on its website and the form TA-2 in the Securities and Exchange Commission database, IST is registered with the Securities and Exchange Commission. An inquiry to IST also confirmed the Company's shares outstanding.

I have (i) met face-to-face with management and a majority of the directors of the Company, (ii) reviewed the Annual Report for the period ending June 30, 2016 as published by the Company through the OTC Disclosure and News Service and (iii) discussed the information with management and a majority of the directors of the Company.

To the best of my knowledge, after inquiry of management and the director of the Company, neither the Company, any 5% holder, nor the undersigned is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

No person other than OTC Markets Group Inc. is entitled to rely on this letter without my prior, written consent. However, OTC Markets Group Inc. is granted full and complete permission and rights to publish the letter through the OTC Disclosure and News Service for viewing by the public and regulators. This letter may not be filed with any governmental agency, other entity or person, without my advance, written consent

Thank you.

Truly yours,



Yeon Joo (Claire) Hsu, Esq.